文献速递消化内镜消化道肿瘤与早癌

随机结肠镜试验对照组腺瘤检出率的变异性:系统综述与Meta分析

Variability in adenoma detection rate in control groups of randomized colonoscopy trials: a systematic review and meta-analysis.
PubMed 文献 · Gastrointest Endosc · 2022-10-13

本系统综述与Meta分析纳入80项随机对照试验的对照组共25,304例患者,评估腺瘤检出率(ADR)的变异性。对照组ADR范围为8.2%至68.1%,异质性高(I²=95.1%),随机效应合并值为37.5%(95%CI 34.6‒40.5)。粪便免疫化学检测作为结肠镜指征是ADR的独立预测因素(OR 1.6,95%CI 1.1-2.4),原发性结肠镜筛查与其他指征的ADR水平无差异。

要点

  • 随机结肠镜试验对照组ADR范围为8.2%至68.1%,异质性I²=95.1%。
  • 粪便免疫化学检测指征是ADR的独立预测因素(OR 1.6,95%CI 1.1-2.4)。
  • 原发性结肠镜筛查与其他指征的ADR水平无差异。

核心结论

  • 随机对照试验对照组ADR水平存在高度变异性。
  • 仅粪便免疫化学检测为基础的结肠镜研究影响基础ADR,原发性结肠镜筛查似乎与其他指征相似。
  • 需要标准化临床、方法学和技术参数相关变量以实现普遍性和可重复性。

研究设计与样本

  • 系统综述与随机效应Meta分析,纳入80项随机对照试验的对照组共25,304例患者。
  • 对照组须使用2008年至2021年间进行的高清白光内镜。
  • 采用多变量混合效应Meta回归分析潜在相关变量,异质性用I²统计量报告。

主要发现

  • 对照组ADR范围为8.2%至68.1%,异质性高(I²=95.1%),随机效应合并值为37.5%(95%CI 34.6‒40.5)。
  • 原发性结肠镜筛查(12项随机对照试验,15%)与混合指征(包括筛查/监测和诊断性结肠镜)的ADR水平无差异。
  • 粪便免疫化学检测作为结肠镜指征是ADR的独立预测因素(OR 1.6,95%CI 1.1-2.4)。
  • 年龄(OR 1.038,95%CI 1.004-1.074)、性别(男性:OR 1.02,95%CI 1.01-1.03)和退镜时间(OR 1.1,95%CI 1.0-1.1)被证实为相关参数。
  • 干预类型(影像学 vs 机械)无影响,但方法学因素有影响:较近的发表年份和较小的样本量与较高的ADR相关。

关键数值与推荐

  • 对照组ADR随机效应合并值为37.5%(95%CI 34.6‒40.5)。
  • 粪便免疫化学检测指征的OR为1.6(95%CI 1.1-2.4)。
  • 年龄的OR为1.038(95%CI 1.004-1.074)。
  • 男性性别的OR为1.02(95%CI 1.01-1.03)。
  • 退镜时间的OR为1.1(95%CI 1.0-1.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 异质性高(I²=95.1%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Adenoma detection rate (ADR) is still the main surrogate outcome parameter of screening colonoscopy, but most studies include mixed indications, and basic ADR is quite variable. We therefore looked at the control groups in randomized ADR trials using advanced imaging or mechanical methods to find out whether indications or other factors influence ADR levels. METHODS: Patients in the control groups of randomized controlled trials (RCTs) on ADR increase using various methods were collected based on a systematic review; this control group had to use high-definition white-light endoscopy performed between 2008 and 2021. Random-effects meta-analysis was used to pool ADR in control groups and its 95% confidence interval (CI) according to clinical (indication and demographic), study setting (tandem/parallel, number of centers, sample size), and technical (type of intervention, withdrawal time) parameters. Interstudy heterogeneity was reported with the I2 statistic. Multivariable mixed-effects meta-regression was performed for potentially relevant variables. RESULTS: From 80 studies, 25,304 patients in the respective control groups were included. ADR in control arms varied between 8.2% and 68.1% with a high degree of heterogeneity (I2 = 95.1%; random-effect pooled value, 37.5%; 95% CI, 34.6‒40.5). There was no difference in ADR levels between primary colonoscopy screening (12 RCTs, 15%) and mixed indications including screening/surveillance and diagnostic colonoscopy; however, fecal immunochemical testing as an indication for colonoscopy was an independent predictor of ADR (odds ratio [OR], 1.6; 95% CI, 1.1-2.4). Other well-known parameters were confirmed by our analysis such as age (OR, 1.038; 95% CI, 1.004-1.074), sex (male sex: OR, 1.02; 95% CI, 1.01-1.03), and withdrawal time (OR, 1.1; 95% CI, 1.0-1.1). The type of intervention (imaging vs mechanical) had no influence, but methodologic factors did: More recent year of publication and smaller sample size were associated with higher ADR. CONCLUSIONS: A high level of variability was found in the level of ADR in the control groups of RCTs. With regards to indications, only fecal immunochemical test-based colonoscopy studies influenced basic ADR, and primary colonoscopy screening appeared to be similar to other indications. Standardization for variables related to clinical, methodologic, and technical parameters is required to achieve generalizability and reproducibility.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Hassan C, Piovani D, Spadaccini M, et al. Variability in adenoma detection rate in control groups of randomized colonoscopy trials: a systematic review and meta-analysis. Gastrointest Endosc. 2022. PMID: 36243103. doi:10.1016/j.gie.2022.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。